| __timestamp | Neurocrine Biosciences, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 675200000 |
| Thursday, January 1, 2015 | 32480000 | 771800000 |
| Friday, January 1, 2016 | 68081000 | 1205500000 |
| Sunday, January 1, 2017 | 169906000 | 1146500000 |
| Monday, January 1, 2018 | 248932000 | 1125800000 |
| Tuesday, January 1, 2019 | 354100000 | 1166100000 |
| Wednesday, January 1, 2020 | 433300000 | 1175500000 |
| Friday, January 1, 2021 | 583300000 | 1111400000 |
| Saturday, January 1, 2022 | 752700000 | 1210100000 |
| Sunday, January 1, 2023 | 887600000 | 1274600000 |
| Monday, January 1, 2024 | 1007200000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Neurocrine Biosciences, Inc. and Perrigo Company plc have demonstrated contrasting approaches to SG&A cost management.
From 2014 to 2023, Neurocrine Biosciences saw a staggering increase in SG&A expenses, growing by nearly 4,800%, reflecting their aggressive expansion strategy. In contrast, Perrigo Company maintained a more stable trajectory, with a 90% increase over the same period, indicating a focus on steady growth and cost efficiency.
By 2023, Perrigo's SG&A expenses were approximately 44% higher than Neurocrine's, highlighting their larger operational scale. This comparison underscores the strategic choices each company makes in balancing growth with cost management, offering valuable insights for investors and industry analysts alike.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Perrigo Company plc Trends and Insights
SG&A Efficiency Analysis: Comparing Amgen Inc. and Perrigo Company plc
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Catalent, Inc. or Perrigo Company plc
Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Perrigo Company plc
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Perrigo Company plc
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Perrigo Company plc